Wet Age-Related Macular Degeneration Market Share Analysis of the Top Industry Players

The market is predominantly driven by the increase in prevalence of AMD, lack of availability of specific treatment, and surge in geriatric population, according to P&S Intelligence.

Lucentis, Eylea, and Avastin are the key drugs available globally for the management of wet AMD. Among these, Eylea is expected to dominate the market during the forecast period. Increasing prevalence of AMD and rise in demand for Eylea are some of the major factors propelling the demand for this drug in the wet age-related macular degeneration market.

Based on the route of administration, the wet age-related macular degeneration market is bifurcated into intravitreally and intravenously administered drugs. During the forecast period, the market is expected to witness faster growth in the category of drugs administered through the intravitreal route, with 7.2% CAGR.

During the forecast period, the wet age-related macular degeneration market is expected to witness the fastest growth in APAC, with 8.8% CAGR. The growth in the APAC wet age-related macular degeneration industry is mainly led by the surge in geriatric population, rise in prevalence of AMD, and medical reimbursements provided by the government for the treatment in the region.

Request to Get the Sample Pages at:  

http://bit.ly/wet-age-related-macular-degeneration-market-b

APAC accounts for more than one-third of the macular generation cases reported globally, which is expected to further increase in the coming years. According to the United Nations projections, around 24% of Asians will be aged 60 years or older by 2050. Since the elderly are at a higher risk of developing AMD, the demand for the required medication for the treatment of the disease is expected to considerably increase in the region in the coming years.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=wet-age-related-macular-degeneration-market

Globally, the wet age-related macular degeneration market is witnessing rapid evolution with a substantial increase in the number of clinical trials conducted for wet AMD drugs. For instance, in February 2019, Outlook Therapeutics Inc. initiated a clinical study to examine the efficacy and safety of ONS-5010 in subjects with wet AMD. The aim of the study is to prevent vision loss by evaluating the effectiveness of ONS-5010 as compared to ranibizumab’s.

The global wet age-related macular degeneration market is marked by the presence of several large players, such as Regeneron Pharmaceuticals Inc., Neurotech Pharmaceuticals Inc., Ophthotech Corporation, Kubota Pharmaceutical Holdings Co. Ltd., Gilead Sciences Inc., Novartis AG, Alimera Sciences Inc., and Bayer AG.

US Benign Prostatic Hyperplasia (BPH) Procedures Market Analysis by Demand, Growth Opportunities

The U.S. benign prostatic hyperplasia (BPH) procedures is expected to grow at a CAGR of 4.2% during 2017-2023.By 2023, the number of BPH procedures performed in the U.S. is expected to reach 215,584.

Growing aging population, rising prevalence of BPH disorders, technological advancements in the BPH procedures and increasing awareness about the BPH disorders and treatments available are the major factors driving the adoption of BPH procedures in the U.S.

Download Report Sample at: 

http://bit.ly/us-bph-procedures

 The advanced research and development activities has led to the development of technologically advanced BPH devices and therapies. Prostatic urethral lift (Urolift system) and targeted sterile water vapor therapy (Rezūm) are some of the recent technological therapies launched for BPH management. Rezūm therapy is a minimally invasive procedure that uses steam in the treatment of enlarged prostate and is currently available in the U.S. These therapies can be performed in a clinic or at an outpatient facility, and thereby reduces the cost associated with hospital stay and surgeries.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=us-bph-procedures

Key player in the U.S. BPH procedures are introducing new advanced products for BPH treatment and gaining public and private insurance coverage. For instance, in May 2017, NeoTract, Inc. announced that its patent UroLift system has received insurance coverage for the treatment of BPH from Cigna Insurance Services Co., a global health service company that provides insurance to over 14 million Americans.

Some of the other key players providing BPH procedures in the U.S. include NxThera, Inc., Boston Scientific Corporation, Urologix, LLC., Convergent Laser Technologies.

Osteoporosis Drugs Market Trends, Drivers, Growth Opportunities

The global osteoporosis drugs market was valued at $8,835.4 million in 2015 and it is expected to grow at a CAGR of 3.8% during 2016-2022.

Among the various classes of osteoporosis drugs, the rank ligand inhibitor segment is expected to witness the fastest growth, a CAGR of 4.3% during the forecast period.

The global osteoporosis drugs market is growing at a significant rate due to growing geriatric population, increasing awareness of osteoporosis and increasing healthcare expenditure. The increasing prevalence of osteoporosis in postmenopausal women and the increasing focus on research & development of new drugs for treatment of osteoporosis are also driving the growth of the global osteoporosis drugs market.

Osteoporosis disease is the most common bone disease, which occurs due to reduced bone mineral density and causes increased risk of fractures and fragile bones. It leads to abnormally porous bones such as sponge, which facilitate the weakening of bones and painful fracture. Most of the spine, hip, shoulder and forearm fractures occur within aged people of 65 years and above.

Download Report Sample at:

http://bit.ly/osteoporosis-drugs-b

Some of the signs and symptoms of the osteoporosis are falling risk and fractures. Diagnostic tests of osteoporosis include X-Ray test and traditional radiography tests, which is further confirmed by bone density test. Osteoporosis disease can be managed by nutrition emphasis, lifestyle management and medicines. The factors such as strict regulatory requirement for the approval of osteoporosis drugs, patent expiry of blockbuster drugs, and side-effects and complications associated with osteoporosis drugs are inhibiting the growth of the global market.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=osteoporosis-drugs-market

Geographically, North America dominated the global market of osteoporosis drugs in 2015; whereas the Asia-Pacific market is expected to witness the fastest growth, a CAGR of 4.2% during the forecast period. This is due to the growing geriatric population, increasing awareness of osteoporosis drugs and increasing healthcare expenditure in the region.

Some of the key companies operating in the global osteoporosis drugs market include Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche, Novartis International AG, Merck & Co. Inc. and Amgen Inc.

Immunotherapy Drugs Market Explores New Growth Opportunities

The global immunotherapy drugs market valued $106.1 billion revenue in 2017 and is projected to register a CAGR of 13.6% during the period 2018–2023.Surge in the prevalence of chronic diseases, and thriving demand and development of monoclonal antibodies (mAbs) are the key factors driving the market growth.

Checkpoint inhibitors and vaccines are the two major types of immunotherapy drugs analyzed in the report. Of these, checkpoint inhibitors held a larger share in the immunotherapy drugs market, accounting for 66.3% in 2017. Checkpoint inhibitors are the first preference for the treatment of chronic diseases, as they provide better and effective treatment results. These drugs act directly on site of action, without delaying the effect of medicine, and are thus being highly adopted for the treatment of several diseases. Some of the major checkpoint inhibitors brand available in the market are Humira, Rituxan/MabThera, Herceptin, Remicade, and Enbrel.

Download Report Sample at:

http://bit.ly/Immunotherapy-Drugs

The report provides epidemiology analysis for cancer, autoimmune and inflammatory diseases, and infectious diseases. According to the International Agency for Research on Cancer (IARC) in 2018, 18.1 million people are estimated to be suffering from cancer globally, which is expected to reach 29.5 million by 2040. Another study conducted by the American Medical Association (AMA) between 2005–2015, reported that the incident of cancer cases increased by 33% during this period, of which 16.4% of the cases were due to aging population.

The market players in the immunotherapy drugs market are actively seeking collaborations and partnerships for the development of novel immunotherapy drugs. For instance, in April 2018, Bristol-Myers Squibb Company (BMS) and Illumina Inc. collaborated to utilize Illumina’s next-generation sequencing (NGS) technology to develop and globally commercialize in-vitro diagnostic (IVD) assays in support of BMS oncology portfolio. The collaboration helped to develop a diagnostic version of Illumina’s TruSight Oncology 500 assay, including tumor mutation burden (TMB), and microsatellite instability for immunotherapies.

Similarly, in April 2018, Pfizer Inc. and Allogene Therapeutics Inc. entered into an asset contribution agreement to use Pfizer’s portfolio related to allogeneic CAR-T therapy, an investigational immune cell therapy, for cancer. This agreement acted as an attractive opportunity for Pfizer Inc. to continue the development of CAR-T therapy.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=immunotherapy-drugs-market

Some of the other leading players operating in the global immunotherapy drugs market are F. Hoffmann-La Roche Ltd., AbbVie Inc., AstraZeneca PLC, Merck & Co. Inc., GlaxoSmithKline plc, Novartis International AG, Johnson & Johnson, Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Sanofi, Medigene AG, C. H. Boehringer Sohn AG & Co. KG, Takeda Pharmaceutical Company Limited, and Celgene Corporation.

Hepatitis Drugs Market Size, Share, Segment Analysis, Growth Drivers and Forecast Report

The global hepatitis drugs market is growing due to increasing incidences of hepatitis and increasing support from government organizations. In addition, the growing geriatric population, and increasing R&D investments on hepatitis research and drug discovery are also driving the growth of the global hepatitis drugs market.

The increasing incidences of various types of hepatitis, such as hepatitis B, and hepatitis C are playing a pivotal role in the growth of the global hepatitis drugs market. According to the Hepatitis B Foundation, a non-profit organization solely dedicated to the global problem of hepatitis B, approximately 400 million people globally were chronically infected with hepatitis B, as reported at the end of September 2015. According to the World Health Organization (WHO), an estimated 130 - 150 million people globally were reported to suffer from hepatitis C, as of July 2015. The increasing incidences of hepatitis have increased the demand of therapeutic drugs for the management of diseases.

Request to Get the Sample Pages at:

However, the high capital expenditure and stringent regulatory requirements are inhibiting the growth of the market. The growing number of collaboration and partnerships is one of the latest trends observed in the market.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=hepatitis-drugs-market

Geographically, North America dominated the global market of hepatitis drugs in 2014; whereas the Asian market is expected to witness the fastest growth, with a CAGR of 32.4% during the forecast period.

The key companies operating in the global hepatitis drugs market include Gilead Sciences Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co. Inc., GlaxoSmithKline PLC, AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, Dynavax Technologies Corporation, and Mitsubishi Tanabe Pharma Corporation.